Yutaka Yasui
YOU?
Author Swipe
View article: Tables S2, S7, S8, S9 from Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer
Tables S2, S7, S8, S9 from Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer Open
Table S2: List of CH mutations identified. Table S7: Mutations analyzed in serial analysis. Table S8: Clinical features of the survivors. Table S9: List of primers used in ddPCR validation.
View article: Figures S1-S10 and Tables S1, S3-S6 from Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer
Figures S1-S10 and Tables S1, S3-S6 from Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer Open
Figure S1: Age distribution of the cohort. Figure S2: The distribution of bleomycin 3rd tertile. Figure S3: Distribution of cancer types treated without alkylating agents, platinum, anthracyclines, bleomycin, dactinomycin, epipodophyllotox…
View article: Supplementary Table S1 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study
Supplementary Table S1 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study Open
Supplementary Table S1: Demographic, treatment, and cancer characteristics by anomaly status.
View article: Data from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study
Data from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study Open
Background:Congenital anomalies are associated with an increased risk of childhood cancer. However, there is a knowledge gap about health outcomes for childhood cancer survivors with congenital anomalies.Methods:We included childhood cance…
View article: Supplementary Table S3 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study
Supplementary Table S3 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study Open
Supplementary Table S3: Rate of chronic health conditions and subsequent malignant neoplasms restricted to those with non-genetic anomalies.
View article: Supplementary Table S2 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study
Supplementary Table S2 from Health Outcomes in Childhood Cancer Survivors with Congenital Anomalies in the Childhood Cancer Survivor Study Open
Supplementary Table S2: Rate of specific chronic health conditions by anomaly status.
View article: Supplementary Materials and Methods from Inference on the Genetic Architecture of Breast Cancer Risk
Supplementary Materials and Methods from Inference on the Genetic Architecture of Breast Cancer Risk Open
Supplementary Material 1 shows mathematical corroboration of the main inference in the paper. Supplementary Material 2 shows the derivation of conditional probability of carrying a specific allele given the co-twin’s allele. Supplementary …
View article: Supplementary Figure from Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study
Supplementary Figure from Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study Open
Supplementary Figure from Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study
View article: Data from Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study
Data from Genome-Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study Open
Background:Gonadotoxic treatment-related infertility has a significant impact on quality of life in childhood cancer survivors. Genome-wide association analyses to delineate the risk of infertility in childhood cancer survivors have not be…
View article: Supplementary Data from Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk
Supplementary Data from Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk Open
This file contains figures S1-5 and Tables S1, 3-9, 12, and 13
View article: Symptom burden, healthcare utilization, and risky behaviors in survivors of the childhood cancer survivor study (CCSS): an observation cohort study
Symptom burden, healthcare utilization, and risky behaviors in survivors of the childhood cancer survivor study (CCSS): an observation cohort study Open
Summary: Background: Childhood cancer survivors face physical, psychological, and neurological symptoms that contribute to risky health behaviors and increased healthcare utilization. Traditional survivorship care models overlook risk asso…
View article: Supplemental Table 4 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 4 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Table 4 shows the top SNP-lipid pairs (LRT <0.01 in SJLIFE) identified through linear regression using continuous lipid traits as endpoints.
View article: Supplemental Figure 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Figure 3 shows an overview of the performed analyses and outcomes.
View article: Supplemental Table 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Table 2 shows the demographic and treatment characteristics of the discovery and replication cohorts, stratified per dyslipidemia status.
View article: Data from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Data from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Background:Dyslipidemia can occur as a long-term side effect of childhood cancer treatment. The difference in prevalence among children receiving comparable treatment suggests a role for genetic variation. We conducted the first genome-wid…
View article: Supplemental Table 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Table 1 depicts the definition and timing of dyslipidemia assessments per cohort.
View article: Supplemental Figure 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Figure 2 shows the QQ plot of the initial discovery analysis.
View article: Supplemental Table 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Table 3 shows the multivariable clinical model, performed in the CCSS Original cohort, to determine treatment factors for stratified GWASs.
View article: Supplemental Figure 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Supplemental Figure 1 shows the flowcharts of the CCSS Original, SJLIFE, CCSS Expansion, and DCCSS-LATER cohorts, indicating included and excluded subjects.
View article: Single rate-limiting event of carcinogenesis
Single rate-limiting event of carcinogenesis Open
Single-cell studies have discovered abundant cancer-associated genetic/phenotypic changes in non-cancerous cells, strikingly contrasting with the infrequency of cancer. Epidemiological data have revealed decades-long plateaus of breast can…
View article: Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older
Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older Open
Background and aim The incidence of hepatocellular carcinoma (HCC) is positively correlated with age, and the population of patients with HCC was also older at the time of clinical diagnosis. In the SURF trial, elderly people aged ≥80 year…
View article: Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report Open
PURPOSE Among childhood cancer survivors, we evaluated not previously explored relationships between colorectal subsequent malignant neoplasm (SMN) incidence and colorectum-specific radiation dose metrics currently used in radiation therap…
View article: Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts Open
Background: Dyslipidemia can occur as a long-term side effect of childhood cancer treatment. The difference in prevalence among children receiving comparable treatment suggests a role for genetic variation. We conducted the first genome-wi…
View article: Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Open
PURPOSE There are limited data on the risk for mortality and health outcomes among the increasing population of older (age >50 years) survivors of childhood cancer during this later stage in life when there is an expected increase in aging…
View article: <i>TTN</i> and <i>BAG3</i> in Cancer Therapy–Related Cardiomyopathy Among Long-Term Survivors of Childhood Cancer
<i>TTN</i> and <i>BAG3</i> in Cancer Therapy–Related Cardiomyopathy Among Long-Term Survivors of Childhood Cancer Open
Importance Cancer therapy–related cardiomyopathy (CCM) is an important concern for childhood cancer survivors. In the general population, rare variants in TTN and BAG3 are associated with an increased risk of familial dilated cardiomyopath…
View article: Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer
Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer Open
View article: Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer Open
View article: Frailty and Sleep in Adult Survivors of Childhood Cancer: A Childhood Cancer Survivor Study Report
Frailty and Sleep in Adult Survivors of Childhood Cancer: A Childhood Cancer Survivor Study Report Open
Background Young adult survivors of childhood cancer exhibit rates of frailty similar to adults several decades older without a cancer history. Frailty has been associated with sleep disturbances in non‐cancer populations, but the relation…
View article: Attributable Risk and Consequences of Bone Mineral Density Deficits in Childhood Cancer Survivors
Attributable Risk and Consequences of Bone Mineral Density Deficits in Childhood Cancer Survivors Open
Importance Data characterizing the severity and changing prevalence of bone mineral density (BMD) deficits and associated nonfracture consequences among childhood cancer survivors decades after treatment are lacking. Objective To evaluate …
View article: Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy Open
Aim We investigated the impact of proteinuria on the therapeutic effect before lenvatinib administration as second‐line treatment after atezolizumab‐bevacizumab. Methods We examined 64 patients who were administered lenvatinib as second‐li…